Dr. Weber is one of our co-founders and has served as a member of our board of directors
since our inception in September 2002, and as the chairman of our board of directors since March 2004. Dr. Weber is also a partner at Domain Associates, L.L.C., a private venture capital management firm focused on life sciences. He has been a founder, founding chief executive officer and board member of multiple biopharmaceutical companies in the Domain portfolio including Cytovia, Inc., Acea Pharmaceuticals, Inc., NovaCardia, Inc., Novalar Pharmaceuticals, Inc., Novacea, Inc., Domain AntiBacterial Acquisition Corporation, Ascenta Therapeutics, Inc., Konova, Inc., Renovia, Inc., Tragara Pharmaceuticals, Syndax Pharmaceuticals and Tobira Therapeutics, Inc. Dr. Weber is currently a member of the board of directors of Novacea, Inc., a publicly held biopharmaceutical company, and he currently serves as interim Chief Executive Officer of Tramoxia Therapeutics, Inc., an early-stage biopharmaceutical company. He is also a current board member of Biovascular, Inc., Ocera, Inc., and Diobex, Inc. Dr. Weber holds a B.S. from Kolping College in Germany and an M.D. from the University of Ulm Medical School in Germany.
Mr. Bock has served as a member of our board of directors since April 2005. Mr. Bock is a Managing Director of Scale Venture Partners, a venture capital firm. He joined Scale Venture Partners in September 1997 from Gilead Sciences, Inc., a biopharmaceutical company, where he held positions in research, project management, business development and sales from September 1989 to September 1997. Prior to Gilead, he was a research associate at Genentech, Inc. from November 1987 to September 1989. He currently serves as a director of Ascenta Therapeutics, diaDexus Inc., SGX Pharmaceuticals, Inc., Horizon Therapeutics and Zogenix, Inc. and is responsible for Scale Venture Partners' investments in Prestwick Pharmaceuticals and Somaxon Pharmaceuticals. Mr. Bock received his B.S. in Biology from California State University, Chico and an M.B.A. from California State University, San Francisco.
Mr. Dovey has served as a member of our board of directors since January 2004. Mr. Dovey is a managing member of Domain Associates, L.L.C., a private venture capital management firm focused on life sciences, and has served in this capacity with the firm since 1988. He has served as chairman of three companies and on the board of directors of approximately 30 additional companies, including Align Technology, Inc. and Cardiac Science, Inc. Mr. Dovey currently serves on the board of Neose Technologies, Inc., a publicly traded company. Prior to joining Domain, Mr. Dovey spent six years at Rorer Group, Inc. (now Aventis), including as president from 1986 to 1988. Previously, he was president of Survival Technology, Inc., a start-up medical products company. He also held management positions with Howmedica, Inc., Howmet Corporation, and New York Telephone. Mr. Dovey has served as both president and chairman of the National Venture Capital Association. He is Chair of the Wistar Institute, a non-profit preclinical biomedical research company. Mr. Dovey is also Co-Dean of the Kauffman Fellows Program at the Center for Venture Education. Mr. Dovey received his B.A. from Colgate University and an M.B.A. degree from the Harvard Business School.
Mr. Lacob has served as a member of our board of directors since January 2004. Since 1987, Mr. Lacob has been a partner at Kleiner Perkins Caufield & Byers, a venture capital firm. He serves on the board of directors of Align Technology, Inc. and eHealth, Inc., as well as several privately held companies, including Opthonix, Inc., AutoTrader.com L.L.C., Codon Devices, Inc. and TherOx, Inc. Mr. Lacob holds a B.S. in biological sciences from the University of California, Irvine, a Master's in Public Health from the University of California, Los Angeles and an M.B.A. from the Stanford Graduate School of Business.
Dr. Powell has served as a member of our board of directors since January 2004. Dr. Powell has been a Managing Director of Sofinnova Ventures, Inc., a venture capital firm, since 1997. He was Group Leader of Drug Delivery at Genentech, Inc. from 1990 to 1997. From 1987 to 1990, he was the Director of Product Development for Cytel Corporation, a biotechnology firm. He has been an Adjunct Professor at the University of Kansas and an editorial board member of several pharmaceutical journals. Dr. Powell also serves on the board of directors of Threshold Pharmaceuticals, Inc. and Anesiva Pharmaceuticals, Inc., as well as several private companies, including Ocera Therapeutics, Inc., Ascenta Therapeutics, Inc., DioBex, Inc. and Saegis Pharmaceuticals, Inc. He received his B.S. and Ph.D. from the University of Toronto and completed his post-doctorate work at the University of California.
Dr. Tollefson has served as our President and Chief Executive Officer and as a member of our board of directors since May 2005. Previously, he spent 13 years at Eli Lilly where he was
President of the Neuroscience Product Group from January 1999 to December 2000 and Vice President of Lilly Research Laboratories from January 1997 to March 2004. Dr. Tollefson's product responsibilities have included Prozac, Strattera, Cymbalta, Symbyax, Serafem, Permax and Zyprexa. Dr. Tollefson has also served as a volunteer Clinical Professor of Psychiatry at Indiana University School of Medicine from April 2004 to the present and has established Consilium, Inc., a consulting company dedicated to psychopharmacological product development. He currently holds the senior guest scientific position at Eli Lilly as the Distinguished Visiting Lilly Research Scholar. Dr. Tollefson has previously worked with over 20 small to mid-size companies on product strategy, clinical development, business development, regulatory affairs and commercial opportunity analyses. He serves on the Boards of Directors for Xenoport, Inc. and Cortex Pharmaceuticals, Inc., each publicly traded companies. Dr. Tollefson obtained his M.D. from the University of Minnesota where he went on to complete a residency in psychiatry and a Ph.D. in psychopharmacology.
Mr. Turner has served as a member of our board of directors since April 2005. Mr. Turner is
a General Partner of Montreux Equity Partners, a position he has held since February 1993. He has 20 years of experience as an entrepreneur, operating manager and venture capitalist. Prior to Montreux, Mr. Turner managed the Turnaround Group for Berkeley International. Previously, Mr. Turner was the founding Chief Financial Officer of Oclassen Pharmaceuticals Inc., a specialty pharmaceutical company focused in dermatology, which merged with Watson Pharmaceuticals. Mr. Turner started his career with Price Waterhouse. He currently serves as a director of Somaxon Pharmaceuticals, Inc, as well as several private companies. Mr. Turner holds a B.S. degree from Sacramento State University (magna cum laude) and attended the MBA program at the Haas School of Business at the University of California, Berkeley, where he has established the Turner Fellowship. Mr. Turner is a Certified Public Accountant.
Stock Information OREX (NASD)
Nov 20, 2008
$4.77 0.63
Quotes delayed at least 20 minutes. Information provided by eSignal.
= Chairman of the Board
= Chair
= Member
= Independent Director
0.63